Guanhao Biotech Co.,Ltd. (SHE:300238)
China · Delayed Price · Currency is CNY 10.95
+0.65 (6.31%)
Nov 5, 2026, 3:04 PM CST
Guanhao Biotech Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 3,008 | 3,672 | 3,192 | 3,596 | 2,726 | 4,913 | |
Market Cap Growth | -28.20% | 15.03% | -11.21% | 31.91% | -44.52% | -26.29% |
Enterprise Value | 2,818 | 3,573 | 3,108 | 3,457 | 2,660 | 4,896 |
Last Close Price | 10.95 | 13.85 | 12.04 | 13.56 | 10.28 | 18.53 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | 217.11 | 150.84 | 116.44 | 115.96 | - | 66.68 |
Forward PE | - | 78.31 | 78.31 | 78.31 | 78.31 | 78.31 |
PS Ratio | 8.72 | 9.47 | 8.46 | 8.90 | 7.23 | 10.05 |
PB Ratio | 5.10 | 7.53 | 6.83 | 7.88 | 6.33 | 6.57 |
P/TBV Ratio | 4.90 | 7.37 | 6.80 | 8.14 | 6.85 | 9.72 |
P/FCF Ratio | - | 110.27 | - | 15555.62 | 91.44 | 41.75 |
P/OCF Ratio | 300.45 | 51.38 | 64.42 | 66.40 | 38.40 | 40.14 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 8.17 | 9.21 | 8.24 | 8.55 | 7.05 | 10.01 |
EV/EBITDA Ratio | 62.79 | 70.05 | 55.66 | 56.53 | - | 51.80 |
EV/EBIT Ratio | 214.92 | 117.30 | 88.16 | 87.19 | - | 71.83 |
EV/FCF Ratio | - | 107.27 | - | 14955.89 | 89.24 | 41.60 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | 0.21 | 0.26 | 0.23 | 0.12 | 0.18 | 0.20 |
Debt / EBITDA Ratio | 2.76 | 2.28 | 1.74 | 0.80 | - | 1.42 |
Debt / FCF Ratio | - | 3.81 | - | 236.51 | 2.65 | 1.29 |
Net Debt / Equity Ratio | -0.17 | -0.07 | 0.00 | -0.11 | -0.11 | -0.01 |
Net Debt / EBITDA Ratio | -2.93 | -0.66 | 0.03 | -0.82 | 1.50 | -0.08 |
Net Debt / FCF Ratio | 4.98 | -1.01 | -0.06 | -218.35 | -1.58 | -0.07 |
Asset Turnover | 0.42 | 0.50 | 0.53 | 0.60 | 0.43 | 0.44 |
Inventory Turnover | 1.19 | 1.16 | 1.05 | 1.32 | 1.58 | 0.94 |
Quick Ratio | 2.13 | 1.15 | 0.95 | 1.04 | 1.10 | 1.06 |
Current Ratio | 2.94 | 1.73 | 1.49 | 1.55 | 1.58 | 1.66 |
Return on Equity (ROE) | 0.21% | 3.09% | 3.60% | 4.75% | -55.57% | 6.93% |
Return on Assets (ROA) | 1.00% | 2.44% | 3.08% | 3.67% | -3.89% | 3.82% |
Return on Invested Capital (ROIC) | 0.29% | 3.58% | 4.78% | 6.60% | -9.80% | 5.59% |
Return on Capital Employed (ROCE) | 1.80% | 4.90% | 6.10% | 7.80% | -11.40% | 8.10% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Earnings Yield | 0.46% | 0.66% | 0.86% | 0.86% | -11.29% | 1.50% |
FCF Yield | -0.66% | 0.91% | -0.83% | 0.01% | 1.09% | 2.40% |
Payout Ratio | 27.03% | 15.07% | 8.99% | 3.89% | - | 9.46% |
Buyback Yield / Dilution | -1.25% | 1.33% | -6.11% | 2.63% | -0.83% | -1.66% |
Total Shareholder Return | -1.25% | 1.33% | -6.11% | 2.63% | -0.83% | -1.66% |